Tumor cells recruit normal endothelial cells (ECs) in the tumor microenvironment, a process which is essential for continued growth and spread of tumors. Numerous oncogenic signaling pathways, including the Src oncoprotein, induce expression of angiogenic factors such as vascular endothelial growth factor (VEGF) that promote tumor angiogenesis. We have shown that the Src kinase regulates VEGF expression through activation of Stat3 signaling in tumor cells. Furthermore, Stat3 is one of the major signaling pathways downstream of Src that is frequently activated in many human tumors, including melanoma and sarcoma. We propose that Src and downstream Stat3 signaling are essential not only for tumor cell survival but also for production of angiogenic factors and their actions on ECs in the tumor microenvironment. Thus, the recent development of clinically-promising pharmacologic Src inhibitors sets the stage for testing a new generation of antitumor and antiangiogenesis therapeutics. The central hypothesis of this proposal is that inhibitors of Src kinase and downstream Stat3 signaling will induce tumor regression through both direct tumor cell apoptosis and impairment of tumor angiogenesis. We will address this hypothesis using a new generation of orally-bioavailable pharmacologic Src inhibitors that are already in early-phase clinical trials. Our focus will be on melanoma and sarcoma because we have shown the important role of Src and downstream Stat3 signaling in these tumor cells. Furthermore, there is a need for more effective therapies in malignant melanoma and sarcoma. The studies proposed here will investigate the molecular mechanisms of action of novel pharmacologic Src kinase inhibitors through the following specific aims: (1) determine the biological effects of Src kinase inhibitors on growth and survival of human melanoma and sarcoma cell lines in culture;(2) assess how inhibition of Src signaling effects production of angiogenesis factors by tumor cells and response to them in tumor ECs;(3) evaluate the effects of Src inhibitors on tumor regression and tumor vasculature in animal models of human melanoma and sarcoma;(4) validate the potential relevance of activated Src signaling in human melanoma and sarcoma clinical specimens. In sum, these studies will provide insights into the mechanism of action of a new generation of pharmacologic Src kinase inhibitors and thereby lay the foundation for more effective molecular-targeted therapy of melanoma and sarcoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA115674-04
Application #
7778282
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Forry, Suzanne L
Project Start
2007-05-01
Project End
2012-02-29
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
4
Fiscal Year
2010
Total Cost
$288,990
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Wen, Wei; Wu, Jun; Liu, Lucy et al. (2015) Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer 14:100
Liu, Lucy; Gaboriaud, Nicolas; Vougogianopoulou, Konstantina et al. (2014) MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells. Cancer Biol Ther 15:178-84
Wen, Wei; Liang, Wei; Wu, Jun et al. (2014) Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther 13:3037-48
Schroeder, Anne; Herrmann, Andreas; Cherryholmes, Gregory et al. (2014) Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res 74:1227-37
Nam, Sangkil; Wen, Wei; Schroeder, Anne et al. (2013) Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol 7:369-78
Warden, Charles D; Lee, Heehyoung; Tompkins, Joshua D et al. (2013) COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. Nucleic Acids Res 41:e117
Nam, Sangkil; Scuto, Anna; Yang, Fan et al. (2012) Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol 6:276-83
Liu, Lucy; Kritsanida, Marina; Magiatis, Prokopios et al. (2012) A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biol Ther 13:1255-61
Nam, Sangkil; Xie, Jun; Perkins, Angela et al. (2012) Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol 6:484-93
Deng, Jiehui; Liu, Yong; Lee, Heehyoung et al. (2012) S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 21:642-54

Showing the most recent 10 out of 28 publications